摘要
Toxoplasma gondii is an obligate intracellular parasite that causes toxoplasmosis. The parasite is ubiquitous, with more than 60 million people in the United States likely infected. (Centers for Disease Control and Prevention, www.cdc.gov/ncidod/dpd/parasites/toxoplasmosis/factsht_toxoplasmosis.htm, accessed May 2006.) Infection can occur by ingestion of parasitic oocysts following handling contaminated soil or cat litter, receiving an infected organ transplant or blood transfusion (rare), or the consumption of contaminated water or food (unwashed garden vegetables). The parasite is rarely of clinical significance in an immunocompetent host. Immunocompromised individuals, newborns, and fetuses (transmission of the tachyzoite form to the fetus can occur via the placenta following primary maternal infection), however, are at high risk for severe or life-threatening disease from toxoplasmosis. T. gondii has been shown to cause chorioretinitis, myocarditis, pneumonitis, and congenital disease. Toxoplasma encephalitis (Toxo encephalitis) is the most common cause of focal encephalitis in patients with AIDS. Toxo encephalitis results from reactivation of chronic latent infection in more than 95 percent of patients. Patients with Toxo encephalitis have single or multiple brain abscesses so their presentation is not specific for Toxo encephalitis. Patients may present with headache, confusion, fever, altered mental status, and neurologic deficits. The typical presentation is a subacute onset with focal neurologic abnormalities in 58 percent to 89 percent of patients. In 15 percent to 30 percent of cases, the clinical presentation may be more abrupt, with seizures or cerebral hemorrhage. Head CT scans in AIDS patients who have Toxo encephalitis reveal multiple ring-enhancing lesions in 70 percent to 80 percent of cases. The thin-walled cavitating lesions with contrast enhancement and surrounding edema often are found in the basal ganglia (approximately 75% cases) or the gray-white matter junction. Magnetic resonance imaging also can be useful for further characterization of the lesions because of its superior sensitivity. Multiple laboratory diagnostic tests are available to diagnose Toxo encephalitis. These include isolation of T. gondii from infected body tissue or fluid by enzyme-linked immunosorbent assay (ELISA) technique, indirect fluorescent antibody, polymerase chain reaction, or hemagglutination testing. Serological tests usually are not helpful because the antibody to T. gondii is so prevalent. If serum tests are negative for T. gondii, an alternative diagnosis should be sought. Cerebrospinal fluid evaluation may be helpful in the diagnostic evaluation of Toxo encephalitis, including differentiation between Toxo, progressive multifocal leukoencephalopathy caused by the JC virus, lymphoma, cytomegalovirus (CMV), or other infectious etiologies. Lumbar puncture is contraindicated if the patient has lesions producing mass-effect or focal signs because of the risk of brain herniation.FigureFigureThe current standard of care allows treatment of Toxo encephalitis to be initiated with a presumptive diagnosis based on the presence of characteristic neuroradiographic findings (e.g., multiple contrast enhancing mass lesions on CT or MRI), findings of clinical neurologic dysfunction, and clinical suspicion of AIDS. Brain toxoplasmosis is considered an AIDS-defining illness with a CD4 less than 100 cells/uL in most cases. This diagnosis should prompt further pertinent evaluations including HIV testing. The differential diagnosis of ring-enhancing lesions on head CT scan is extensive, including metastatic disease, demyelinating disease, infection/septic emboli, post-radiation changes, resolving hematoma, and infarction. In patients with advanced AIDS who have CNS findings, physicians must consider, in addition to common bacterial causes of encephalitis, Toxo encephalitis (50% of all brain lesions in AIDS patients), primary CNS lymphoma associated with Epstein-Barr virus (30% of all brain lesions in AIDS patients), progressive multifocal leukoencephalopathy (JC virus), HIV encephalopathy (HIV), CMV encephalitis (CMV), tuberculosis, cryptococcus, histoplasmosis, candidiasis, coccidioidomycosis, aspergillosis, trypanosomiasis, herpetic meningoencephalitis, neurocysticercosis, meningovascular syphilis, and amoebic abscesses. The standard treatment of choice for Toxo encephalitis is a combination of pyrimethamine, sulfadiazine, and leucovorin (folinic acid) to reduce hematologic toxicity. This treatment regimen is generally reserved for immunocompromised patients with acute infection, reactivation of chronic infection, or patients with congenital infection. Pyrimethamine (Daraprim) is a folic acid antagonist that selectively inhibits plasmodial dihydrofolate reductase. It is highly selective against plasmodia and T gondii, and is a Category C medication. Primary therapy should be given for at least six weeks. Although most patients respond to Toxo encephalitis treatment (60% to 90%), the long-term prognosis is guarded because the risk of death from dementia may be increased. (Inf Dis 2006; 12[2]:111.) Anticonvulsants should be given to those patients who seize, and steroids should be considered for all patients with clinically significant brain edema. Chronic suppressive therapy may be indicated after initial treatment. For patients with a CD4 T-cell count less than 100 cells/uL and positive Toxo serology, oral TMP-SMX is recommended for prophylaxis. Patients who are HIV-positive should begin antiretroviral therapy. All patients with clinically significant Toxo encephalitis require admission and antiparasitic therapy. With appropriate pharmacological therapy, patients should show clinical improvement in two to three weeks, or an alternative diagnosis should be sought. Our patient was found to have an absolute CD4 T-cell count of 29. Cerebrospinal fluid revealed an elevated total protein of 53 mg/dL, a red blood count of 285 /uL, and a white blood count of 35 /uL with 16% segmented neutrophils and 81% lymphocytes. He was presumptively diagnosed with Toxo encephalitis, and discharged home on hospital day three on the appropriate medical regimen with appointments for appropriate follow-up.